Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan

<b>Background/Objectives:</b> <i>Clostridioides difficile</i> infection (CDI) poses a significant healthcare challenge, with recurrence rates reaching 30%, leading to substantial morbidity and costs. Fidaxomicin (FDX) and bezlotoxumab (BEZ) have shown potential in reducing recurrence; however, real-...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Jun Hirai, Nobuaki Mori, Yuki Hanai, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	MDPI AG 2025-02-01
Ráidu:	Antibiotics
Fáttát:	bezlotoxumab fidaxomicin combination therapy <i>Clostridioides difficile</i> recurrence severe diarrhea
Liŋkkat:	https://www.mdpi.com/2079-6382/14/3/228
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!